Results 311 to 320 of about 2,576,885 (397)

Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations [PDF]

, 2011
Bunten, Hannah, Liang, Wei-Jun, Osselton, David M., Pounder, Derrick   +3 more
core  

The Financial Sustainability of Programs to Initiate Medications for Opioid Use Disorder in Emergency Department Settings

Academic Emergency Medicine, EarlyView.
ABSTRACT Background The US is experiencing an epidemic of opioid misuse and mortality. Effective treatments are available, including medications for opioid use disorders (MOUD), but they are greatly underused due to a variety of barriers. In response, some US hospitals have established programs to identify emergency department (ED) patients with opioid
Dominic Hodgkin, Cindy Parks Thomas, Margot T. Davis, Jennifer J. Wicks, Shelly F. Greenfield, Zachary F. Meisel, Constance M. Horgan   +6 more
wiley   +1 more source

Study of Antidepressant Actions of Subanesthetic Nitrous Oxide: Importance of Adequate Blinding and Opioid Receptors. [PDF]

Biol Psychiatry Glob Open Sci
Gillman MA.
europepmc   +1 more source

Drug Use After Emergency Department‐Initiated Injectable Buprenorphine: A Secondary Analysis of the ED‐INNOVATION Ancillary Safety and Feasibility Trial

Academic Emergency Medicine, EarlyView.
ABSTRACT Study Objective To characterize opioid and nonopioid drug use in the week following emergency department (ED)‐initiated extended‐release buprenorphine (XR‐BUP) treatment using both self‐reported data and urine drug screens (UDS). Methods This study uses data collected during a nonrandomized clinical trial of patients with untreated opioid use ...
Ethan Cowan, Gail D'Onofrio, Jeanmarie Perrone, Erik Anderson, James Dziura, Kathryn Hawk, Andrew Herring, Ryan McCormack, Manali Phadke, Elizabeth A. Samuels, David A. Fiellin   +10 more
wiley   +1 more source

Total-body imaging of mu-opioid receptors with [¹¹C]carfentanil in non-human primates. [PDF]

Eur J Nucl Med Mol Imaging
Hsieh CJ, Hou C, Lee H, Tomita C, Schmitz A, Plakas K, Dubroff JG, Mach RH.   +7 more
europepmc   +1 more source

Effects of cannabidiol in alcohol use disorder patients with and without co‐occurring post‐traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof‐of‐concept trials

Alcohol, Clinical and Experimental Research, EarlyView.
Two small placebo‐controlled trials evaluated the effects of cannabidiol (CBD) in patients with alcohol use disorder (AUD), with and without co‐occurring post‐traumatic stress disorder (PTSD). CBD was rapidly absorbed and generally well tolerated in dosages of up to 1200 mg/day. Both treatment groups showed large reductions in drinking.
Michael P. Bogenschutz, Esther Blessing, Danielle Dgheim, Dayeon Cho, Jun Zhang, Eugene M. Laska, Charles R. Marmar   +6 more
wiley   +1 more source

Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism. [PDF]

Addict Neurosci
Bedard ML, Huang XP, Murray JG, Nowlan AC, Conley SY, Mott SE, Loyack SJ, Cline CA, Clodfelter CG, Dasgupta N, Krumm B, Roth BL, McElligott ZA.   +12 more
europepmc   +1 more source

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Acute Stress Increases Striatal Connectivity With Cortical Regions Enriched for μ and κ Opioid Receptors. [PDF]

Biol Psychiatry
Zhukovsky P, Ironside M, Duda JM, Moser AD, Null KE, Dhaynaut M, Normandin M, Guehl NJ, El Fakhri G, Alexander M, Holsen LM, Misra M, Narendran R, Hoye JM, Morris ED, Esfand SM, Goldstein JM, Pizzagalli DA.   +17 more
europepmc   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source